echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > [a week] up! Up! The bid price of Shanghai's volume procurement rose unexpectedly! "Biopharmaceutical" fat meat of upper medicine and lower mouth; Drug Administration provides clinical technical guidance and escort for NSCLC

    [a week] up! Up! The bid price of Shanghai's volume procurement rose unexpectedly! "Biopharmaceutical" fat meat of upper medicine and lower mouth; Drug Administration provides clinical technical guidance and escort for NSCLC

    • Last Update: 2019-09-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Point 1 this week Up! Up! The bid price of Shanghai's volume procurement rose unexpectedly! 2 The "bio medicine" fat of the upper medicine and the lower mouth; 3 The drug administration provides NSCLC with clinical technical guidance and escort; 4 Alarm! After the vaccine case, St Changsheng is about to usher in the "delisting", falling down the altar of regret! On September 18, 2019, the 10th China (Taizhou) International Pharmaceutical exposition hosted by the people's Government of Jiangsu Province was solemnly opened in the exhibition center of China Pharmaceutical City, Taizhou, Jiangsu Province The pharmaceutical Expo lasted for 3 days, among which, the 10th China (Taizhou) International Pharmaceutical Expo, chemical drug R & D and international development forum, sponsored by China Pharmaceutical City, hosted by pharmaceutical intelligence network and co organized by high level talents Association of Taizhou pharmaceutical high tech Zone, was successfully held in the afternoon of that day The participants commented that @ Xiaoqi is true that the strength of domestic pharmaceutical enterprises is strong or weak The R & D of new drugs should consider their own strength The pharmaceutical enterprises with strength should take the responsibility to let domestic new drugs go abroad, so as to connect with the world and improve the overall level of domestic R & D @Li Chaoyang's conference, the rich information knowledge, multi angle situation review, detailed data report and unique views brought by many industry's gakes to the forum, all of which broadened my vision, clarified my thinking and pointed out the direction of the forum How to set up R & D projects in the post "4 + 7" era by Dr Zhang ran'an is considered from three dimensions Depending on the post-4 + 7 situation, there should be four different countermeasures At the end of the paper, it is pointed out that "there are always market opportunities, only a pair of insight and enough courage are needed" Dr Sun Liying's report on the similarities and differences and development trend of new drug review between China and the United States (legend, domestic industry, agriculture, military and business, later came to the United States to become DFA official, now returned to China for development) is really impressive, which makes me understand that the two newspapers are not as difficult as I expected, and it is possible to do well in the courses ICH requires that unified standards and guidelines must be implemented, which is the same day as the world Coming soon Mr murali variyath from India brought "generic drug development India and China" By introducing the development process of generic drugs in India and the characteristics of the current development of Chinese and Indian drugs, I know that there are many opportunities and prospects for cooperation in this field in addition to competition Dr Zhang Tianyi's speech topic "clinical development strategy of China us new drug double newspaper" can make a powerful Pharmaceutical companies challenge this field and take less detours; the international development trend and progress of Chinese chemical drugs, written by Mr Li Tianquan (co founder of yaozhi.com), analyzes and judges the present and future with a large number of data, which has a strong guiding significance for enterprise decision-making In particular, he also brought the achievement of "big data of 40 years of Chinese pharmaceutical research and development" published by China Pharmaceutical press, which is not only highly readable, but also extremely convenient as a reference book Wang xiangxu, chairman of the board of directors, made a speech on the development of medicine in India His words constantly radiated with innate humor cells Ppt also made very new ideas, taking us into another ancient civilization country, visiting the development of chemical medicine and opportunities for domestic cooperation with it At the end of the forum, Mr Li Tianquan also presided over a round table forum on the theme of "research and development of chemical generic drugs and international response strategies after the new deal" Dr Wu Jianjun and chairman Fu Xueqi had their own unique views and brilliant speeches The time is fleeting Four and a half hours pass in a flash One is more wonderful than the other, and the amount of information is huge I have to review it carefully to understand the truth I hope to have the opportunity to participate in such meetings again in the future At the end of the forum, Mr Li Tianquan also presided over a round table forum on the theme of "research and development of chemical generic drugs and international response strategies after the new deal" Dr Wu Jianjun and chairman Fu Xueqi had their own unique views and brilliant speeches The time is fleeting Four and a half hours pass in a flash One is more wonderful than the other, and the amount of information is huge I have to review it carefully to understand the truth I hope to have the opportunity to participate in such meetings again in the future On September 18, the State Drug Administration issued a circular to guide the clinical technology of NSCLC, which was sponsored by the drug regulatory bureau of the State Administration of drugs, and issued the technical guidelines for the end point of clinical trials of advanced non-small cell lung cancer, aiming to standardize and guide the clinical trial design and end point selection of drugs for the treatment of advanced non-small cell lung cancer in China, and provide reference technical specifications Lung cancer is widely recognized as the world's highest incidence rate cancer According to statistics, in 2015, there were about 787 thousand new lung cancer cases in China and 631 thousand deaths Among them, non-small cell lung cancer (NSCLC) accounts for 85% of the total lung cancer Another characteristic of lung cancer is that most of the patients are in the late stage at the time of diagnosis, so the overall five-year survival rate is only about 20% How to improve the survival rate of patients has become the focus of current research, and the huge space to fill in the whole lung cancer field is also the focus of many drug manufacturers In 2018, 320 tumor clinical trials were added in China, an increase of 56% year on year, including 149 new phase I clinical trials, 69 new phase II clinical trials and 98 new phase III clinical trials At present, the treatment goal of advanced NSCLC is also in line with the research direction, that is, to prolong the life of patients and improve the quality of life From the current market, "small molecule tyrosine kinase inhibitors", "anti angiogenic drugs" and "immunocheckpoint inhibitors" are the main three types of therapeutic drugs at this stage In recent years, PD-1 / PD-L1 mAb, a variety of immunosuppressive checkpoint inhibitors, has its own unique features in the treatment of early lung cancer, especially in the long-term effect benefit, greatly reducing the deterioration rate of early lung cancer, but the effective rate of single drug treatment is low, while the short-term effect is not significant, which is a major deficiency, so it is different from other drugs It is an important direction for the future development of this kind of drugs to combine the use of biomarkers, select the target treatment population and improve the efficacy Basic medical care is very important, and the medical insurance bureau has made an important reply Recently, the State Medical Insurance Bureau has replied to the No 2856 proposal of the second session of the 13th National People's Congress It analyzes in detail how the State Medical Insurance Bureau will establish the medical insurance policy to adapt to the development of basic medical care from four aspects, and puts forward the next measures for the key content As for the problem that medical expenses can only be reimbursed once within three days, the State Medical Insurance Bureau replied that the medical insurance departments of all regions have not issued the regulation that medical expenses can only be reimbursed once within three days However, in most areas, in order to prevent medical institutions from decomposing hospitalization or reducing service quality, it is required that if the insured is hospitalized again due to the same disease within two weeks after discharge, the corresponding expenses of medical institutions shall be deducted In this regard, the next step of the medical insurance department will further promote the construction of the handling service system including urban and rural residents' medical insurance, standardize the handling process by means of institutional construction and information construction, and provide the people with standard, convenient and efficient handling services On the issue of drug allocation in grass-roots medical and health institutions, the medical insurance bureau pointed out that in 2019, the national health and Health Commission issued the notice on Further Strengthening the use management of basic drug allocation in public medical institutions, which explicitly encouraged the establishment of a unified drug purchase catalogue and supply guarantee mechanism in urban medical groups and county medical communities, and led the hospital to take effective measures Measures to strengthen the role of pharmacists in higher medical institutions in guiding and supporting the use of drugs in lower medical institutions, and gradually realize the homogenization of drug supply and pharmaceutical care In the next step, the Department of health will continue to guide all localities to implement the requirements of the circular, adhere to the dominant position of basic drugs, and promote public medical institutions to fully equip and give priority to the use of basic drugs At the same time, we should encourage all localities to standardize and unify the varieties, dosage forms and specifications of drugs used by medical institutions within their jurisdiction, promote the experience and practice of drug use connection within the Medical Association, strengthen the division of labor and cooperation within the Medical Association (urban medical group and county medical community), establish a unified drug purchase catalogue and supply guarantee mechanism, and promote the flow of pharmaceutical service resources of medical institutions at higher and lower levels We should improve the level of homogeneity of pharmaceutical care, promote the connection of drug use between primary medical and health institutions and secondary and tertiary hospitals, and achieve coordinated drug use The industry is booming! Up! The bid price of Shanghai's volume procurement rose unexpectedly! On September 18, Shanghai Sunshine pharmaceutical purchase network released the publicity of the results of the planned selection of the centralized volume purchase of drugs in Shanghai in 2019, which publicized the results of the planned selection of the centralized volume purchase of drugs in Shanghai (purchase document No.: sh-dl2019-1) Among them, fluconazole tablets were selected in Sichuan Kelun pharmaceutical industry, bisoprolol fumarate tablets in Chengdu Yuandong biopharmaceutical industry, glimepiride tablets in Shandong Xinhua Pharmaceutical Industry and ambroxol hydrochloride tablets in Jiangsu Hengrui pharmaceutical industry Except for Kelun, the winning enterprises of the three varieties have changed The most surprising thing about this volume purchase is that in the volume purchase in Shanghai last year, the average price of fluconazole tablets of Kelun Pharmaceutical Co., Ltd was about 0.33 yuan per tablet, and after the consistency evaluation this year, the winning price rose to about 0.95 yuan per tablet, an increase of 188% Coincidentally, Hengrui pharmaceutical also took ambroxol hydrochloride tablets at a price of about 0.24 yuan / tablet, which was increased by about 172% compared with the bidding price of about 0.09 yuan / tablet of Yuxin pharmaceutical last year In addition, the bid price of bisoprolol fumarate and glimepiride tablets is slightly lower than that of last year's bid price, so that the original bid winning drugs that fail to pass the consistency evaluation are replaced by generic drugs that pass the consistency evaluation This can not help but make people think about the significance of two varieties of prices rising instead of falling Did the selected enterprises last year make profits by purchasing drugs with volume? Does the cost of drugs increase after consistency evaluation? Will last year's price be the lowest point of volume purchase? Therefore, the insiders speculate that the biggest possibility of this increase instead of decrease may lie in the rising cost brought by the consistency evaluation, and the enterprises increase the quotation On the other hand, the resource market is gradually inclined to large enterprises with strong production capacity, and small enterprises are gradually marginalized In addition, it may also indicate that the price of the evaluated varieties involved in the volume purchase has reached the bottom stage It's not the purpose to strive for the best Individual drugs may have better results depending on the market environment The enterprise's production capacity and clinical data of drugs will become an important evaluation standard for volume purchase in the future On September 18, Shanghai Pharmaceutical announced the progress of establishing a joint venture with foreign investment Sphprojectbiocadlimited, a wholly-owned subsidiary of Shanghai pharmaceutical, signed the joint venture agreement between Shanghai Pharmaceutical and BioCad and the shareholders agreement on sph-biocad (HK) Limited with biocadhk on September 17, and will establish a new joint venture with a registered capital of US $40000000 For a long time, the label of Shanghai pharmaceutical industry is "pharmaceutical circulation", but this time, the company obtained six large varieties of biological drugs by "Introduction" From the variety, there are many popular products in the field of biological drugs, such as adalimumab, trastuzumab and PD-1 inhibitor It can be seen that the determination of Shanghai Pharmaceutical transformation and layout of biological drugs is very strong In addition, public information shows that in 2019, China
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.